Edition:
United Kingdom

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

15.35EUR
20 Jun 2019
Change (% chg)

€0.09 (+0.59%)
Prev Close
€15.26
Open
€15.13
Day's High
€15.40
Day's Low
€15.13
Volume
14,633
Avg. Vol
275,288
52-wk High
€44.20
52-wk Low
€7.59

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.44
Market Cap(Mil.): €1,956.98
Shares Outstanding(Mil.): 24.10
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -5.32 -- --
ROI: -54.08 14.23 13.82
ROE: -57.09 15.46 15.24

BRIEF-DBV Technologies: Potential Long-Term Benefit Of Viaskin Peanut

* ANNOUNCED ON SATURDAY THE COMPANY WILL PRESENT DATA FROM EPICUTANEOUS IMMUNOTHERAPY AT EAACI 2019

03 Jun 2019

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO

06 Mar 2019

BRIEF-DBV Technologies To Resubmit Biologics License Application For Viaskin Peanut In Q3 2019

* ANNOUNCED ON WEDNESDAY UPDATE ON REGULATORY STATUS OF VIASKIN PEANUT FOR THE TREATMENT OF PEANUT-ALLERGIC CHILDREN 4 TO 11 YEARS OF AGE

14 Feb 2019

Earnings vs. Estimates